ClinicalTrials.gg
RecruitingNCT04660487Updated Dec 31, 2025

Relationship Between "FODMAPs" and "GVHD"

An observational study in Graft Versus Host Disease, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by The First Affiliated Hospital of Soochow University · Observational

How we know

From the registry’s dates

  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Graft vs Host Disease with a site in China — 38 open to participants now, 43 under way, 8 of them phase 3. Graft vs Host Disease · China.

Started
2020
with 6 others
Observational
9 of 81
7 open now
Primary completion
2026-12
later than 16 of 42 live
Registered
28th of 81
by date
Lead sponsor
7 of 81
The First Affiliated Hospital of Soochow University

Among the 81 studies in Graft vs Host Disease with a site in China, this one is one of 7 that started in 2020, is one of 9 observational ones, reaches primary completion later than 16 of the 42 other live ones, and was the 28th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

38 of the 81 studies in Graft vs Host Disease with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Graft vs Host Disease with a site in China, or all of them as a file.
02

Study summary

With the stem cell transplanting increasing, patients which effected with "GVHD" were also increased. To evaluation the relationship between "FODMAPs" and "GVHD", Bone marrow transplant patients were recruited.

Read the detailed description

The feces were collected from the patients who had been successfully transplanted after bone marrow transplantation. After 24 hours of culture in the culture medium, the degradation rate of "FODMAPs" was detected, and the relationship between the degradation rate and the occurrence time and degree of "GVHD" was observed

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Successful bone marrow colonization after bone marrow transplantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of "AML","ALL","MDS" or "MM" Disease;
  2. Must be treated with bone marrow transplantation;
  3. The transplanted bone marrow was successfully planted

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal diseases;
  2. Age>60; or Age\<10;
  3. Probiotics or prebiotics were taken before enrollment
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Occurrence of GVHD

    The occurrence time and degree of GVHD

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
  • 中国
    Suzhou, Jiangsu 215006, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 72 months after the start.

Of 45 non-industry observational studies under Graft vs Host Disease, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 154. This study's planned 72 months is above that.

Counting every sponsor, half of 46 studies reached it within 60 months; a quarter within 37 and three quarters within 154.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2020
First posted
Dec 9, 2020
StartActual
Dec 1, 2020
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04660487
Responsible party
Qi Xiao-Fei (Dean, The First Affiliated Hospital of Soochow University) — Principal investigator
First posted
Dec 9, 2020
Start date
Dec 1, 2020
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 31, 2025

Study contacts

xiaofei qi
Contact
qixf-sz@hotmail.com
+13812616208
Depei Wu
Contact
wudepei@suda.edu.cn
+13812616208
Depei Wu
study chair · SOOCHOW UNIV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion